EE630 A Cost-Effectiveness Analysis (CEA) of Adjuvant Nivolumab for Patients With Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in France
Abstract
Authors
C Paul M Massetti FE Cotte R Moreau S Kassahun P Singh I Kim AF Gaudin H Leleu